Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cytarabine + Methotrexate + Methylprednisolone |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cytarabine | Cytosar-U | Ara-C | Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309). | |
Methotrexate | Abitrexate | Amethopterin | Chemotherapy - Antimetabolite 14 | Methotrexate is an antimetabolite, which inhibits DHFR resulting in decreased immune function and antineoplastic activity and is FDA approved for psoriasis, RA, and several cancers including choriocarcinoma, AML, lung, head and neck and epidermoid (FDA.gov). |
Methylprednisolone | Artisone-Wyeth | 6alpha-Methylprednisolone |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05303792 | Phase II | Cytarabine + Methotrexate + Methylprednisolone Cyclophosphamide + Dexamethasone + Mesna + Vincristine Sulfate Cytarabine + Inotuzumab ozogamicin + Methotrexate + Methylprednisolone Cyclophosphamide + Dexamethasone + Inotuzumab ozogamicin + Mesna + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Mesna + Rituximab + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Inotuzumab ozogamicin + Mesna + Rituximab + Vincristine Sulfate Cytarabine + Methotrexate + Methylprednisolone + Rituximab Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cytarabine + Inotuzumab ozogamicin + Methotrexate + Methylprednisolone + Rituximab | Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma | Active, not recruiting | USA | 1 |